Breakthrough treatment for ovarian cancer displays promising results
pharmafile | June 5, 2017 | News story | Research and Development, Sales and Marketing | Amgen, Cancer, ICR, ovarian cancer
A treatment that specifically targets ovarian cancer cells has shown that half of women who took the drug experienced shrinking of their tumours. In the cases where women possessed a particular molecular target, seven out of ten women were found to respond positively.
The drug trial is still in its very early stages, coming as it does as part of Phase 1 trials into the drug. The trial consisted of 15 women and was set up to determine its safety in humans, as opposed to attempting to display therapeutic effect.
However, the drug, known as ONX-0801, was able to show immediate improvements to seven women on the trial who had undergone all other forms of treatment.
The treatment functions by mimicking folic acid to enter cancer cells; once this has happened, the drug is able to kill the cell by blocking a molecule called thymidylate synthase, which then causes irreparable DNA damage.
This targeted method of treatment means that healthy cells are not damaged as part of the treatment. As a result, the drug is able to produce its effects without the negative side-effects that arise as part of a regimen involving chemotherapy.
Professor Paul Workman, Chief Executive of the ICR, said: “It’s really exciting to see such positive results in an early-stage trial. ONX-0801 is the latest in a long line of precision cancer medicines to have been discovered here at the ICR – 20 since 2005 alone. The drug works in a particularly clever way by mimicking the effects of folic acid to hit cancer cells selectively while leaving healthy tissue alone. It looks a highly promising treatment with the potential to have huge benefits for women with ovarian cancer, and I’m very keen to see it progress to later-stage trials.”
As Workman mentions latterly, there are still far more trials for the drug to undergo before it can become routine treatment. There are worries that the drug may have safety risks if taken for more than a few months at a time. However, this will be discovered as more research and more trials are conducted. The overall impression is that the drug holds a lot of promise for treatment, particularly for those women have no other options left.
The news comes as positive news for the company that owns the compound, Amgen, and its subsidiary, Onyx Pharmaceuticals, that is developing the drug.
Ben Hargreaves
Related Content
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …
